Lupin Buys Stake In South Africa’s Pharma Dynamics; Aims To Be In Top 3
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After months of negotiations, Indian generic drug maker Lupin acquired a 60 percent equity stake in South Africa's sixth largest generic drug maker Pharma Dynamics with the goal of joining the top ranks of companies in South Africa in three years
You may also be interested in...
India’s Lupin Set For Global Generics Growth; Logs 53 Percent Profit Jump In Q2
NEW DELHI - Indian drug maker Lupin said it was poised to grow further in the global generics market as it reported a 53 percent jump in consolidated quarterly net profit, driven by a strong across-the-board performance
India’s Lupin Set For Global Generics Growth; Logs 53 Percent Profit Jump In Q2
NEW DELHI - Indian drug maker Lupin said it was poised to grow further in the global generics market as it reported a 53 percent jump in consolidated quarterly net profit, driven by a strong across-the-board performance
Ranbaxy Disappointed By U.S. FDA’s Warning Letters And “Import Alert”
MUMBAI - India's largest drug maker Ranbaxy expressed its disappointment over U.S. FDA's move to issue warning letters and import alerts against drug products manufactured at its sites in Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh